ATE398126T1 - Azaindolinhibitoren von mtp und apob - Google Patents

Azaindolinhibitoren von mtp und apob

Info

Publication number
ATE398126T1
ATE398126T1 AT05754288T AT05754288T ATE398126T1 AT E398126 T1 ATE398126 T1 AT E398126T1 AT 05754288 T AT05754288 T AT 05754288T AT 05754288 T AT05754288 T AT 05754288T AT E398126 T1 ATE398126 T1 AT E398126T1
Authority
AT
Austria
Prior art keywords
azaindolin
hibitors
apob
mtp
azaindolin hibitors
Prior art date
Application number
AT05754288T
Other languages
English (en)
Inventor
Alyx Guevel
Catherine Vidal
Bruno Roux
Olivier Chevreuil
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Application granted granted Critical
Publication of ATE398126T1 publication Critical patent/ATE398126T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT05754288T 2004-07-27 2005-06-28 Azaindolinhibitoren von mtp und apob ATE398126T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0408302A FR2873694B1 (fr) 2004-07-27 2004-07-27 Nouveaux aza-indoles inhibiteurs de la mtp et apob

Publications (1)

Publication Number Publication Date
ATE398126T1 true ATE398126T1 (de) 2008-07-15

Family

ID=34948943

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05754288T ATE398126T1 (de) 2004-07-27 2005-06-28 Azaindolinhibitoren von mtp und apob

Country Status (16)

Country Link
US (1) US7838533B2 (de)
EP (1) EP1771446B1 (de)
JP (1) JP5161569B2 (de)
AR (1) AR050436A1 (de)
AT (1) ATE398126T1 (de)
AU (1) AU2005266662B2 (de)
CA (1) CA2575223C (de)
CY (1) CY1108306T1 (de)
DE (1) DE602005007494D1 (de)
DK (1) DK1771446T3 (de)
ES (1) ES2308510T3 (de)
FR (1) FR2873694B1 (de)
PL (1) PL1771446T3 (de)
PT (1) PT1771446E (de)
SI (1) SI1771446T1 (de)
WO (1) WO2006010423A2 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008012219A (es) 2006-04-03 2008-10-02 Santaris Pharma As Composicion farmaceutica que comprende oligonucleotidos antisentido anti-miarn.
MY162210A (en) 2006-04-03 2017-05-31 Roche Innovation Ct Copenhagen As Pharmaceutical composition
EP2061767B1 (de) 2006-08-08 2014-12-17 Sanofi Arylaminoaryl-alkyl-substituierte Imidazolidin-2,4-dione, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Arzneimittel und ihre Verwendung
DE102007005045B4 (de) 2007-01-26 2008-12-18 Sanofi-Aventis Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DK2149605T3 (da) 2007-03-22 2013-09-30 Santaris Pharma As Korte RNA antagonist forbindelser til modulering af det ønskede mRNA
JP2010521193A (ja) 2007-03-22 2010-06-24 サンタリス ファーマ アー／エス Ａｐｏ−ｂ１００発現の阻害のためのｒｎａアンタゴニスト化合物
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
MY156951A (en) 2007-10-04 2016-04-15 Santaris Pharma As Micromirs
DE102007063671A1 (de) 2007-11-13 2009-06-25 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US8361980B2 (en) 2008-03-07 2013-01-29 Santaris Pharma A/S Pharmaceutical compositions for treatment of microRNA related diseases
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
EP2315832B1 (de) 2008-08-01 2015-04-08 Roche Innovation Center Copenhagen A/S Micro-rna-vermittelte modulation koloniestimulierender faktoren
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
JP5773535B2 (ja) 2009-04-24 2015-09-02 ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブＲｏｃｈｅ Ｉｎｎｏｖａｔｉｏｎ Ｃｅｎｔｅｒ Ｃｏｐｅｎｈａｇｅｎ Ａ／Ｓ インターフェロンに非応答性のｈｃｖ患者の治療のための医薬組成物
US8563528B2 (en) 2009-07-21 2013-10-22 Santaris Pharma A/S Antisense oligomers targeting PCSK9
CN102482312A (zh) 2009-08-26 2012-05-30 赛诺菲 新颖的杂芳族氟代糖苷结晶水合物、含有这些化合物的药物和它们的用途
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120058A1 (de) 2011-03-08 2012-09-13 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
EP2683698B1 (de) 2011-03-08 2017-10-04 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683702B1 (de) 2011-03-08 2014-12-24 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683703B1 (de) 2011-03-08 2015-05-27 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
JP2014518223A (ja) * 2011-06-20 2014-07-28 アルツハイマーズ・インスティテュート・オブ・アメリカ・インコーポレイテッド 化合物とその治療用途
DK3013959T3 (da) 2013-06-27 2020-02-17 Roche Innovation Ct Copenhagen As Antisense-oligomerer og konjugater målrettet pcsk9
AR117472A1 (es) 2018-12-21 2021-08-11 Celgene Corp Inhibidores de tienopiridina de ripk2

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3362956A (en) * 1965-08-19 1968-01-09 Sterling Drug Inc 1-[(heterocyclyl)-lower-alkyl]-4-substituted-piperazines
US3511841A (en) * 1967-05-29 1970-05-12 Sterling Drug Inc 1-((4-,5-,6-,and 7-azaindolyl)-lower-alkyl)- 4-substituted-piperazines
US4939159A (en) * 1986-09-10 1990-07-03 Sandoz Pharm. Corp. Azaindole derivatives useful as cholesterol biosynthesis inhibitors
DE4435477A1 (de) * 1994-10-04 1996-04-11 Bayer Ag Cycloalkano-indol- und -azaindol-derivate
CN1522246B (zh) * 2001-06-28 2010-04-21 辉瑞产品公司 三酰胺取代的吲哚、苯并呋喃及苯并噻吩
US6861440B2 (en) * 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
JPWO2003101983A1 (ja) * 2002-05-31 2005-09-29 アステラス製薬株式会社 テトラヒドロピラン誘導体
DE10229777A1 (de) * 2002-07-03 2004-01-29 Bayer Ag Indolin-Phenylsulfonamid-Derivate
JP4737495B2 (ja) * 2004-01-14 2011-08-03 塩野義製薬株式会社 エリスロマイシン誘導体

Also Published As

Publication number Publication date
DE602005007494D1 (de) 2008-07-24
EP1771446A2 (de) 2007-04-11
WO2006010423A2 (en) 2006-02-02
JP2008508198A (ja) 2008-03-21
AU2005266662B2 (en) 2011-04-21
FR2873694A1 (fr) 2006-02-03
EP1771446B1 (de) 2008-06-11
CY1108306T1 (el) 2014-02-12
FR2873694B1 (fr) 2006-12-08
JP5161569B2 (ja) 2013-03-13
ES2308510T3 (es) 2008-12-01
SI1771446T1 (sl) 2008-10-31
CA2575223A1 (en) 2006-02-02
AR050436A1 (es) 2006-10-25
US20090036481A1 (en) 2009-02-05
CA2575223C (en) 2013-08-06
PL1771446T3 (pl) 2008-10-31
PT1771446E (pt) 2008-09-17
WO2006010423A3 (en) 2006-03-02
US7838533B2 (en) 2010-11-23
AU2005266662A1 (en) 2006-02-02
DK1771446T3 (da) 2008-09-22

Similar Documents

Publication Publication Date Title
ATE398126T1 (de) Azaindolinhibitoren von mtp und apob
DE602005012267D1 (de) N von geräten
DE602005011285D1 (de) Formmasse von polymer
DE602005019971D1 (de) Inhibitoren von cysteinprotease
ATE423121T1 (de) Diphenylimidazopyrimidin- und -imidazolamine als b-sekretase-inhibitoren
ATE521604T1 (de) N-substituierte benzimidazolyl-c-kit-inhibitoren und kombinatorische benzimidazolbibliothek
ATE557025T1 (de) Inhibitoren von dipeptidylpeptidase iv auf pyrrolopyridinbasis und verfahren
DE602004005753D1 (de) Kombinationen von harzzusammensetzungen und verwendungsverfahren dafür
ATE493421T1 (de) Neue inhibitoren von chymase
ATE410421T1 (de) P38 inhibitor und anwendungsverfahren dafür
DE602005015382D1 (de) Effektives und robustes Routing unabhängig von Verkehrsänderungen
DE602005007987D1 (de) achtelung und -entschachtelung
DE502005006286D1 (de) Verwendung von trisubstituierten benzopyranonen
DK1675852T3 (da) Heterocykliske 7-amino-alkylidenyl-quinoloner og -naphthyridoner
FI20030261A (fi) Iskulaite
DE602005009321D1 (de) Hinonen und 3-o-geschützten morphinondienolcarboxylaten
DE502004011575D1 (de) Verwendung von Dioldimerfettsäureestern
DE602007012260D1 (de) Nitratester von piperidinen
DE602004031527D1 (de) Kombination von serotonin-wiederaufnahme-hemmern und agomelatin
ATE468342T1 (de) Azolopyridin-2-on-derivate als inhibitoren von lipasen und phospholipasen
ATE495163T1 (de) Benzothiazol-2-on-derivate als inhibitoren von lipasen und phospholipasen
DE602005001066D1 (de) Komplexe Emulsionen von Perfluoropolyethern
ATE409477T1 (de) Kombination von voriconazol und einem antifungalen cyp2c19-inhibitor
DE112004002972A5 (de) Gefederter und zusammenlegbarer Schlitten
DE502004009045D1 (de) Injizierbare darreichungsform von flupirtin

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1771446

Country of ref document: EP